Third quarter 2026 earnings call, November 4, 2026

International Flavors & Fragrances reported third quarter results that were clean on the top line but carried a more cautious message on near-term profitability than the headline beat suggests. Management raised the low end of both full-year guidance ranges, to sales of $7.5 billion to $7.6 billion and adjusted operating EBITDA of $1.55 billion to $1.6 billion. The same outlook also signals a Q4 in which margins moderate, sales growth slows to roughly 3%, and price-to-input-cost turns unfavorable. The raise of the floor, with the ceiling unchanged, reads more as a narrowing of risk than a lift in expectations.

Input Costs Are the New Problem, and Q1 2027 Looks Like the Trough

The most consequential new information on the call concerned cost inflation. CFO Michael DeVeau said the largest increases come from oil derivatives, including their effect on energy and logistics, and that the pressure is "pretty broad-based" across Taste, Scent and Health & Biosciences. Asked whether the roughly 3% raw material inflation that dsm-firmenich flagged for 2027 resonated, he said the figure "feels right" and is consistent with current trends. He attributed part of it to the run-rate effect of higher Brent crude prices on petrochemicals, logistics and energy, with some broader raw material inflation on top.

Recovery depends on pricing, and the timing is unfavorable. IFF is in the middle of annual pricing negotiations that run through December, and DeVeau said Q4 price-to-input-cost will be negative because of lag. His calendarization was specific: the gap will be widest in Q1 2027, should narrow each quarter after that, and could "flip to a positive number" later in the year. Management did not offer a timeline for full parity, and it declined to give specifics when pressed by Baird. Procurement productivity is meant to offset part of the burden. Investors should read this as a likely drag on first-half 2027 margin progression, even though the company has been delivering volume-led margin expansion, with Q3 adjusted operating EBITDA margin up 20 basis points to 20.8%.

Health & Biosciences: A Three-Part Q4 Margin Squeeze

Health & Biosciences was the weak spot. Segment sales rose only 1% to $566 million, with a decline in the Health unit offsetting mid-single-digit growth in food biosciences and grain processing. Management attributed the weakness to a soft end market. CEO Erik Fyrwald said consumers in the U.S. and Europe have cut dietary supplement spending under economic pressure, and he acknowledged that "the market is very soft" and that the recovery "is just taking time."

DeVeau laid out three drivers for Q4 H&B margin pressure. First, Health volume softness hurts mix, since Health is one of the company's higher-margin businesses. Second, unfavorable net price to input costs, which he said stems from logistics and energy, while raw materials are "pretty benign." Third, the timing of reinvestment in R&D and commercial resources, which he described as temporary. The mix and reinvestment items are less likely to resolve quickly than the pricing issue, and no turnaround date for Health was offered. The one product-level positive was the launch of GutABAlite, the first new Health product in several years, which management said has drawn strong early customer interest. No financial contribution was quantified.

Fyrwald said Food Biosciences should keep growing at a high-single-digit rate and that the broader enzymes portfolio is posting solid growth, which implies the problem is confined to Health rather than the enzyme franchise as a whole.

Taste and Scent Deliver Volume-Led Growth

Taste sales rose 6% to $687 million, with growth in every region. Greater Asia was up double digits, Latin America up high single digits, EMEA up mid-single digits and North America up low single digits. Segment EBITDA rose 7% to $128 million. Scent sales grew 6% to $689 million, with consumer fragrance up high single digits and fine fragrance and fragrance ingredients each up mid-single digits. Scent EBITDA rose 10% to $139 million. In both segments, volume was the primary driver of profit growth.

Management credited new wins and an innovation pipeline that has been rebuilt over the past two years. Fyrwald said that in consumer fragrance, IFF is "getting more than our fair share," and that fine fragrance delivered mid-single-digit growth against a strong double-digit prior-year comparison, helped by new wins in Europe and North America. The Middle East has stabilized with some signs of growth, though he said the company remains cautious given the geopolitical backdrop. In Taste, he pointed to wins with global key accounts and a push into regional and local customers, citing an event in New Jersey attended by 135 customers. Asked about the cycle, he said, "I think we're still early in the game."

Several analysts asked for quantification of the contribution from new wins, and none was given. Fyrwald said only that "a lot of our growth is coming from the new wins" and that they arrive "at the base or higher margins." Investors should treat the claim as directional. On the GLP-1 question, he said IFF leaned in early, helped by his Eli Lilly board experience, and sees demand for protein, fiber and reduced sugar and sodium as a durable trend rather than a fad. He did not size the opportunity.

Q4 Growth Slows, but Management Rules Out Destocking

Q4 currency-neutral sales growth is guided to about 3%, plus or minus, compared with 5% to 6% in Q2 and Q3. When Deutsche Bank asked whether customer destocking was a factor, DeVeau said no. He pointed to a harder prior-year comparison and noted that on a two-year stacked basis Q4 is "almost the same number" as Q3. He added that Q4 sales trends are "currently solid." Fyrwald separately said a 4% to 6% top-line range remains achievable in a normalized environment for Scent, Taste and Health & Biosciences alike.

Food Ingredients Separation, Stranded Costs and Cash

The $4.3 billion sale of Food Ingredients to CVC Capital Partners remains on track to close by the end of the first half of 2027. IFF also completed the sale of Soy Crush, Concentrates and Lecithin and has agreed to divest botanical extracts, vitamins and minerals, and food enhancement businesses, with closing expected by year-end. Continuing operations now consist of Taste, Scent and Health & Biosciences.

Stranded costs remain at about $100 million, with two-thirds targeted for elimination within 12 months of closing. Actions include renegotiating third-party contracts, moving work into the global business services organization, technology-driven efficiencies and resizing the organization. DeVeau said the only real execution risk is balancing separation work with the stranded cost program, and he characterized dis-synergy reinvestment, such as lab separations and some commercial resources, as "minimal."

Cash generation improved. Nine-month free cash flow was $371 million, up $245 million year on year, and management has tied incentive compensation to a free cash flow conversion metric. Payables, however, remain a constraint. DeVeau expects them to be roughly flat in Q4, partly because separation requirements may force prepayment of some invoices, and he called extending payment terms the biggest remaining working capital opportunity.

On the balance sheet, net debt to credit adjusted EBITDA rose to 2.75x from the short-term debt used to fund the completed $500 million accelerated share repurchase, which retired about 5.8 million shares, or roughly 2.3% of shares outstanding. The company is not planning further buybacks in Q4 and expects to repay the debt with Food Ingredients proceeds. That leaves a $2.5 billion authorization largely unused until after the transaction closes.